Advanced NSCLC: Interpreting Data From the POSEIDON Trial

A brief review of the POSEIDON trial, which analyzed durvalumab with or without tremelimumab in combination with chemotherapy in advanced NSCLC.

Related Videos
Henry S. Park, MD, MPH
Expert on lung cancer
Anne Chiang, MD, PhD
Sarah Goldberg, MD, MPH
Experts on prostate cancer
Experts on prostate cancer
Ferdinandos Skoulidis, MD, PhD, MRCP
Experts on DTC
Related Content